Search research articles
Contact Us
Filters
Showing results (181-190 of 230) with videos related to
Page
of 23
Sort By:
The Oncologist
|
October 17, 2024
Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma
Bixia Tang, Jun Xiao, Zhihong Chi, et al.
Journal for Immunotherapy of Cancer
|
February 23, 2022
Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
Siming Li, Xiaowen Wu, Xieqiao Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 28, 2020
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Xinan Sheng, Xieqiao Yan, Lin Wang, et al.
BMC Cancer
|
February 7, 2023
Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study
Chuanliang Cui, Yu Chen, Zhiguo Luo, et al.
Journal for Immunotherapy of Cancer
|
February 6, 2025
Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights
Xuan Wang, Hui Tian, Zhihong Chi, et al.
Frontiers in Oncology
|
June 7, 2021
Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-<i>Ad hoc</i> Analyses of Pooled Data From Two Clinical Trials
Xue Bai, Jie Dai, Caili Li, et al.
Frontiers in Oncology
|
September 10, 2021
Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial
Lili Mao, Ya Ding, Xue Bai, et al.
Signal Transduction and Targeted Therapy
|
November 21, 2024
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial
Jiayong Liu, Xuan Wang, Zhongwu Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2017
Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy
Yan Kong, Xinan Sheng, Xiaowen Wu, et al.
Journal of Extracellular Vesicles
|
March 26, 2025
Dynamic Change of PD-L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti-PD-1 Therapy
Linzi Sun, Xiaoting Wei, Qian Zhao, et al.
Page
of 23
Search research articles
Search
Showing results (181-190 of 230) with videos related to
Sort By:
Page
of 23
The Oncologist
|
October 17, 2024
Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma
Bixia Tang, Jun Xiao, Zhihong Chi, et al.
Journal for Immunotherapy of Cancer
|
February 23, 2022
Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
Siming Li, Xiaowen Wu, Xieqiao Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 28, 2020
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Xinan Sheng, Xieqiao Yan, Lin Wang, et al.
BMC Cancer
|
February 7, 2023
Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study
Chuanliang Cui, Yu Chen, Zhiguo Luo, et al.
Journal for Immunotherapy of Cancer
|
February 6, 2025
Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights
Xuan Wang, Hui Tian, Zhihong Chi, et al.
Frontiers in Oncology
|
June 7, 2021
Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-<i>Ad hoc</i> Analyses of Pooled Data From Two Clinical Trials
Xue Bai, Jie Dai, Caili Li, et al.
Frontiers in Oncology
|
September 10, 2021
Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial
Lili Mao, Ya Ding, Xue Bai, et al.
Signal Transduction and Targeted Therapy
|
November 21, 2024
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial
Jiayong Liu, Xuan Wang, Zhongwu Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2017
Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy
Yan Kong, Xinan Sheng, Xiaowen Wu, et al.
Journal of Extracellular Vesicles
|
March 26, 2025
Dynamic Change of PD-L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti-PD-1 Therapy
Linzi Sun, Xiaoting Wei, Qian Zhao, et al.
Page
of 23